These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19079758)

  • 1. ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.
    Qin L; Gilbert PB; Follmann D; Li D
    Ann Appl Stat; 2008 Mar; 2(1):386-407. PubMed ID: 19079758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating candidate principal surrogate endpoints.
    Gilbert PB; Hudgens MG
    Biometrics; 2008 Dec; 64(4):1146-54. PubMed ID: 18363776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling.
    Huang Y
    Biometrics; 2018 Mar; 74(1):27-39. PubMed ID: 28653408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and estimation for evaluating principal surrogate markers in vaccine trials.
    Huang Y; Gilbert PB; Wolfson J
    Biometrics; 2013 Jun; 69(2):301-9. PubMed ID: 23409839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
    Gilbert PB; Bosch RJ; Hudgens MG
    Biometrics; 2003 Sep; 59(3):531-41. PubMed ID: 14601754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Likelihood-based methods for evaluating principal surrogacy in augmented vaccine trials.
    Liu W; Zhang B; Zhang H; Zhang Z
    Stat Methods Med Res; 2017 Apr; 26(2):984-996. PubMed ID: 25549966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating a surrogate endpoint at three levels, with application to vaccine development.
    Gilbert PB; Qin L; Self SG
    Stat Med; 2008 Oct; 27(23):4758-78. PubMed ID: 17979212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Likelihood-Based Methods for Assessing Principal Surrogate Endpoints in Vaccine Trials.
    Huang Y; Dasgupta S
    Stat Biosci; 2019 Dec; 11(3):504-523. PubMed ID: 33033531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled effects approach to assessing immune correlates of protection.
    Gilbert PB; Fong Y; Kenny A; Carone M
    Biostatistics; 2022 Jul; ():. PubMed ID: 35848843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled effects approach to assessing immune correlates of protection.
    Gilbert PB; Fong Y; Kenny A; Carone M
    Biostatistics; 2023 Oct; 24(4):850-865. PubMed ID: 37850938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hard, harder, hardest: principal stratification, statistical identifiability, and the inherent difficulty of finding surrogate endpoints.
    Wolfson J; Henn L
    Emerg Themes Epidemiol; 2014; 11():14. PubMed ID: 25342953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous Inference of Treatment Effect Modification by Intermediate Response Endpoint Principal Strata with Application to Vaccine Trials.
    Zhuang Y; Huang Y; Gilbert PB
    Int J Biostat; 2019 Jul; 16(1):. PubMed ID: 31265429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented designs to assess immune response in vaccine trials.
    Follmann D
    Biometrics; 2006 Dec; 62(4):1161-9. PubMed ID: 17156291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change Point Inference in the Presence of Missing Covariates for Principal Surrogate Evaluation in Vaccine Trials.
    Yang T; Huang Y; Fong Y
    Biometrika; 2021 Dec; 108(4):829-843. PubMed ID: 35001938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SENSITIVITY ANALYSIS FOR EVALUATING PRINCIPAL SURROGATE ENDPOINTS RELAXING THE EQUAL EARLY CLINICAL RISK ASSUMPTION.
    Huang Y; Zhuang Y; Gilbert P
    Ann Appl Stat; 2022 Sep; 16(3):1774-1794. PubMed ID: 37008748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.
    Gilbert PB; Hudgens MG; Wolfson J
    Int J Biostat; 2011; 7(1):Article 36. PubMed ID: 22049267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.
    Li Z; Gilbert P; Nan B
    Biometrics; 2008 Dec; 64(4):1247-55. PubMed ID: 19032178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.
    Gilbert PB; Huang Y
    Epidemiol Methods; 2016 Dec; 5(1):93-112. PubMed ID: 28154793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.